Elizabeth D. Krell Sells 6,000 Shares of AtriCure Inc. (ATRC) Stock
AtriCure Inc. (NASDAQ:ATRC) Director Elizabeth D. Krell sold 6,000 shares of the stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $15.93, for a total value of $95,580.00. Following the sale, the director now owns 20,162 shares in the company, valued at approximately $321,180.66. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
AtriCure Inc. (NASDAQ:ATRC) opened at 16.24 on Monday. AtriCure Inc. has a 12 month low of $13.44 and a 12 month high of $26.88. The stock’s market capitalization is $539.20 million. The company has a 50 day moving average price of $15.24 and a 200 day moving average price of $15.52.
AtriCure (NASDAQ:ATRC) last announced its earnings results on Thursday, August 4th. The medical device company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.04. AtriCure had a negative return on equity of 20.88% and a negative net margin of 24.48%. The firm had revenue of $39.70 million for the quarter, compared to analysts’ expectations of $39.84 million. During the same quarter in the previous year, the company earned ($0.18) earnings per share. The firm’s quarterly revenue was up 21.8% compared to the same quarter last year. Equities research analysts predict that AtriCure Inc. will post ($1.16) earnings per share for the current year.
A number of brokerages have commented on ATRC. Needham & Company LLC reiterated a “buy” rating and set a $20.00 target price (down previously from $23.00) on shares of AtriCure in a report on Monday, August 8th. JMP Securities began coverage on AtriCure in a report on Thursday, June 30th. They set an “outperform” rating and a $25.00 target price on the stock. Canaccord Genuity reiterated a “buy” rating on shares of AtriCure in a report on Tuesday, July 12th. BTIG Research reissued a “buy” rating and set a $19.00 price target (down previously from $34.00) on shares of AtriCure in a research note on Wednesday, August 10th. Finally, Stifel Nicolaus reduced their price target on AtriCure from $26.00 to $21.00 and set a “buy” rating on the stock in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $20.13.
A number of large investors have recently made changes to their positions in ATRC. Bank of New York Mellon Corp boosted its stake in shares of AtriCure by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 134,237 shares of the medical device company’s stock valued at $1,896,000 after buying an additional 4,302 shares during the last quarter. Essex Investment Management Co. LLC raised its position in AtriCure by 9.4% in the second quarter. Essex Investment Management Co. LLC now owns 79,076 shares of the medical device company’s stock valued at $1,117,000 after buying an additional 6,818 shares during the period. Skylands Capital LLC raised its position in AtriCure by 68.4% in the second quarter. Skylands Capital LLC now owns 92,597 shares of the medical device company’s stock valued at $1,308,000 after buying an additional 37,597 shares during the period. Perkins Capital Management Inc. raised its position in AtriCure by 1.1% in the second quarter. Perkins Capital Management Inc. now owns 85,100 shares of the medical device company’s stock valued at $1,202,000 after buying an additional 900 shares during the period. Finally, Metropolitan Life Insurance Co. NY raised its position in AtriCure by 3.4% in the first quarter. Metropolitan Life Insurance Co. NY now owns 20,347 shares of the medical device company’s stock valued at $342,000 after buying an additional 661 shares during the period. 77.26% of the stock is currently owned by hedge funds and other institutional investors.
AtriCure Company Profile
AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.